The COVID-19 Pandemic and Its Positive Impact on RNA Drug Development
News
Article
Pharmaceutical TechnologyThe Real Message Behind Commercial mRNA Products, April 2023 eBook
Volume 2023 eBook
Issue 3
Pages: 18–21
The COVID-19 pandemic helped to showcase RNA molecules and their therapeutic potential. There were also lessons learned in terms of drug delivery, manufacturing, logistics, and storage.
M.Rode-Foto - Stock.adobe.com
RNA-based therapeutics have been in development for decades. The RNA drug development trend was on the rise in early 2000s; however, its popularity went down due to unique challenges. The COVID-19 pandemic helped to bring a spotlight on RNA molecules and their therapeutic potential.There were also lessons learned in terms of drug delivery, manufacturing, logistics and storage. This is the silver lining of the pandemic, where necessity and emergency need for vaccine and therapy highlighted potential solutions. Hopefully, it also opens the door for novel RNA therapeutics.
Read this article in Pharmaceutical Technology’s The Real Message Behind Commercial mRNA Products eBook.
About the author
Marina Necdina is a business development manager, former pharma analyst, and research scientist.
Article details
Pharmaceutical Technology
eBook: The Real Message Behind Commercial mRNA Products
April 2023
Pages: 18–21
Citation
When referring to this article, please cite it as Necdina, M. The COVID-19 Pandemic and Its Positive Impact on RNA Drug Development. Pharmaceutical Technology's The Real Message Behind Commercial mRNA Products eBook (April 2023).
Editor's note: This article was original published online on Feb. 1, 2023 and updated on April 11, 2023 to include missing text.
Articles in this issue
Stability in mRNA-LNP Formulations
Nucleic Acid-based Therapeutics Are Stepping into the Spotlight
Learning to Think at Lightspeed
Managing mRNA Instability
The Role of Separation Techniques in the Analysis of mRNA Therapeutic Drug Substances and Drug Products
The Marriage of RNA and Mass Spectrometry
Delivering on the Potential of mRNA Therapeutics
The COVID-19 Pandemic and Its Positive Impact on RNA Drug Development
Recent Videos
Related Content
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Article
Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
